ApoC-III content of apoB-containing lipoproteins is associated with binding to the vascular proteoglycan biglycan
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Retention of apolipoprotein (apo)B and apoE-containing lipoproteins by extracellular vascular proteoglycans is critical in atherogenesis. Moreover, high circulating apoC-III levels are associated with increased atherosclerosis risk. To test whether apoC-III content of apoB-containing lipoproteins affects their ability to bind to the vascular proteoglycan biglycan, we evaluated the impact of apoC-III on the interaction of [(35)S]SO(4)-biglycan derived from cultured arterial smooth muscle cells with lipoproteins obtained from individuals across a spectrum of lipid concentrations. The extent of biglycan binding correlated positively with apoC-III levels within VLDL (r = 0.78, P < 0.01), IDL (r = 0.67, P < 0.01), and LDL (r = 0.52, P < 0.05). Moreover, the biglycan binding of VLDL, IDL, and LDL was reduced after depletion of apoC-III-containing lipoprotein particles in plasma by anti-apoC-III immunoaffinity chromatography. Since apoC-III does not bind biglycan directly, enhanced biglycan binding may result from a conformational change associated with increased apo C-III content by which apoB and/or apoE become more accessible to proteoglycans. This may be an intrinsic property of lipoproteins, since exogenous apoC-III enrichment of LDL and VLDL did not increase binding. ApoC-III content may thus be a marker for lipoproteins characterized as having an increased ability to bind proteoglycans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 LDL binds to biglycan with high affinity. A: Autoradiograph of a gel from the electrophoretic gel mobility shift assay is shown. Increasing concentrations of VLDL, IDL, and LDL from a subject were incubated with a fixed amount (0.19 𝛍 M) of [ 35 S]SO4-labeled biglycan for 1 h at 37 ° C prior to electrophoresis in agarose, as described in Materials and Methods. Biglycan that binds lipoproteins remains at the origin, or migrates a short distance into the gel. Free, unbound [ 35 S]SO4-biglycan migrates to the front of the gel. B: The binding curves for the interaction of VLDL (circle), IDL (square), and LDL (triangle) and [ 35 S]SO4-labeled biglycan that were shown in A. The amount of bound versus free [ 35 S]SO4-biglycan for each lane was calculated, and plotted against the concentration of total protein for that lipoprotein sample. The inset shows the same data as a Scatchard plot. Data are from a single experiment that is representative of lipoprotein samples from 24 subjects.](https://figures.cochat.ai/paper-figures/47acf12c2c17455b9e5b69f9a1c02a91/apoc-iii-content-of-apob-containing-lipoproteins-is-associated-with-binding-to-figure-1.png)
![Fig. 2 Within each lipoprotein class, the amount of apoC-III correlates positively with the ability of the lipoprotein to bind biglycan. Hyperbolic regression curves are shown to demonstrate the correlation of a lipoprotein's apoC-III content with the amount of biglycan bound to samples of lipoprotein (VLDL, circle; IDL, square; LDL, triangle) that contained 0.05 mg/ml total protein. For the interaction, samples were incubated with a fixed amount (0.19 𝛍 M) of [ 35 S]SO4-labeled biglycan for 1 h at 37 ° C prior to electrophoresis in agarose, as described in Materials and Methods.](https://figures.cochat.ai/paper-figures/6d564be98af9412eabaaf31603a5bd49/apoc-iii-content-of-apob-containing-lipoproteins-is-associated-with-binding-to-figure-2.png)
![Fig. 3 Within each lipoprotein class, the amount of apoC-III correlates with the affinity constant ( Ka ) for the interaction of the lipoprotein with biglycan. Hyperbolic regression curves are shown to demonstrate the correlation of a lipoprotein's apoC-III content with the affinity constant ( Ka ) calculated from the interaction with biglycan (VLDL, circle; IDL, square; LDL, triangle). For the interaction, samples were incubated with a fixed amount (0.19 𝛍 M) of [ 35 S]SO4-labeled biglycan for 1 h at 37 ° C prior to electrophoresis in agarose, as described in Materials and Methods.](https://figures.cochat.ai/paper-figures/1d4dc0f8e7f64d03bb874756cda7f58a/apoc-iii-content-of-apob-containing-lipoproteins-is-associated-with-binding-to-figure-3.png)
![Fig. 4 Increased binding of biglycan to lipoproteins that contain apoC-III compared to apoC-III-depleted lipoproteins. Binding curves are shown for the interaction of biglycan and apoC-III-containing (A) VLDL, (B) IDL, and (C) LDL (open circle), or VLDL, IDL, and LDL isolated from the same plasma sample that had been passed over an anti-human apoC-III column (closed circle). Equal numbers of lipoprotein particles were incubated with a fixed amount (0.19 𝛍 M) of [ 35 S]SO4-labeled biglycan for 1 h at 37 ° C prior to electrophoresis in agarose, as described in Materials and Methods. The insets show the same data as Scatchard plots. The data are from a single experiment that is representative of two independent experiments.](https://figures.cochat.ai/paper-figures/68456f2f4ec547ad8bf3dfad19e053f3/apoc-iii-content-of-apob-containing-lipoproteins-is-associated-with-binding-to-figure-4.png)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“VLDL and remnants are also enriched in apoE and apoCIII, both implicated in binding and retention in the artery wall.5,71,125”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 317,331 · cited 1×
“LDL protein concentrations were determined by a modification of the method of Lowry, et al. ( 25 ) using BSA as the standard.”
MethodPhosphorus Assay in Column Chromatography
Bartlett, G. R. (1959) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)70226-3 · Cited by 12,801 · cited 1×
“Phospholipids were measured using a standardized colorimetric method (24) and a phosphorous calibrator (Sigma Chem.”
MethodThe Response-to-Retention Hypothesis of Early Atherogenesis
Williams, K. J., & Tabas, I. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.5.551 · Cited by 1,413 · cited 1×
“Kinetic analyses suggest that the trapping of lipoproteins by arterial wall proteoglycans is due to selective retention rather than increased delivery of the lipoproteins (4, 8).”
BackgroundMolecular modeling of protein-glycosaminoglycan interactions.
Cardin, A. D., & Weintraub, H. J. (1989) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.9.1.21 · Cited by 1,301 · cited 3×
“This is consistent with the presence of heparin/proteoglycan binding regions on both apoB and apoE (5, 36 ).”
BackgroundResultInfluentialFisher, L. W., Termine, J. D., & Young, M. F. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)83781-4 · Cited by 702
Mahley, R. W., & Ji, Z.-S. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33334-4 · Cited by 693
Blood Lipids and Lipoproteins: Quantitation, Composition and Metabolism
(1973) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1973.tb128705.x · Cited by 554
Chait, A., Brazg, R. L., Tribble, D. L., & Krauss, R. M. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90144-e · Cited by 554 · cited 1×
“Along with being more susceptible to oxidative modification than large LDL (50, 51), small, dense LDL particles have been hypothesized to have greater permeability and have been suggested to have enhanced affinity for arterial wall proteoglycans (7, 52).”
BackgroundSelf-citation[24] Nondenaturing polyacrylamide gradient gel electrophoresis
Nichols, A. V., Krauss, R. M., & Musliner, T. A. (1986) · Methods in Enzymology · doi:10.1016/0076-6879(86)28084-2 · Cited by 521 · cited 1×
“Particle size measurement of apoB-containing lipoproteins was performed on plasma and isolated lipoprotein fractions using non-denaturing 2–14% polyacrylamide gradient gel electrophoresis (GGE) and standardized conditions (23).”
MethodSelf-citationSuperoxide-mediated modification of low density lipoprotein by arterial smooth muscle cells.
Heinecke, J. W., Baker, L., Rosen, H., & Chait, A. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112371 · Cited by 517
Self-citation
Cited by
Borén, J., Chapman, M. J., Krauss, R. M., Packard, C. J., Bentzon, J. F., Binder, C. J., Daemen, M. J., Demer, L. L., Hegele, R. A., Nicholls, S. J., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz962 · Cited by 1,601
Self-citationGinsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab551 · Cited by 979
“in apoE and apoCIII, both implicated in binding and retention in the artery wall.(5,71,125) These factors enhance remnant cholesterol deposition in the plaque;(71,126,127) indeed, unlike LDL, remnant particle entry exceeds efflux.”
BackgroundBorén, J., & Williams, K. J. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000330 · Cited by 524
“The mechanism has been unclear because apoC-III by itself lacks positively charged domains to bind arterial-wall proteoglycans [51].”
BackgroundNakashima, Y., Wight, T. N., & Sueishi, K. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn099 · Cited by 299
“LDL, very-low-density lipoprotein (VLDL), and intermediatedensity lipoprotein (IDL).(73) Overexpression of human biglycan by rat SMCs results in production of an ECM with increased high-affinity lipoprotein binding.”
BackgroundSelf-citationApolipoproteins in vascular biology and atherosclerotic disease
Mehta, A., & Shapiro, M. D. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00613-5 · Cited by 273
Karlsson, H., Leanderson, P., Tagesson, C., & Lindahl, M. (2005) · PROTEOMICS · doi:10.1002/pmic.200401010 · Cited by 241
Hypertriglyceridemia secondary to obesity and diabetes
Subramanian, S., & Chait, A. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.10.003 · Cited by 200
Self-citationThe Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans
Borén, J., Packard, C. J., & Taskinen, M.-R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00474 · Cited by 196
Kaysen, G. A., & Eiserich, J. P. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000111744.00916.e6 · Cited by 183
“Apolipoprotein C III (apo C III), a competitive inhibitor of lipoprotein lipase is increased in CKD. Serum triglyceride levels increase as a result of accumulation of intermediatedensity lipoprotein (IDL) comprising VLDL and chylomicron remnants.”
BackgroundInfluentialApolipoprotein C-III: from pathophysiology to pharmacology
Norata, G. D., Tsimikas, S., Pirillo, A., & Catapano, A. L. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.07.001 · Cited by 182
“As example, in patients with HTG and T2DM, apoC-III-enriched LDL exhibited an altered lipid composition compared with apoC-III-free LDL, increased binding to proteoglycans and lipoprotein retention, and increased LDL susceptibility to hydrolysis and aggregation by sphingomyelinase (Figure 3) [32,66,67].”
BackgroundSacks, F. M. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000146 · Cited by 168
Hiukka, A., Ståhlman, M., Pettersson, C., Levin, M., Adiels, M., Teneberg, S., Leinonen, E. S., Hultén, L. M., Wiklund, O., Orešič, M., et al. (2009) · Diabetes · doi:10.2337/db09-0206 · Cited by 141
“The mechanisms involved are unclear, as apoCIII does not bind directly to proteoglycans (14).”
BackgroundSwarbrick, M. M., Stanhope, K. L., Elliott, S. S., Graham, J. L., Krauss, R. M., Christiansen, M. P., Griffen, S. C., Keim, N. L., & Havel, P. J. (2008) · British Journal of Nutrition · doi:10.1017/s0007114508968252 · Cited by 131
Self-citationRetention of atherogenic lipoproteins in the artery wall and its role in atherogenesis
Fogelstrand, P., & Borén, J. (2011) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2011.09.007 · Cited by 154
Molecular Interactions Leading to Lipoprotein Retention and the Initiation of Atherosclerosis
Khalil, M. F., Wagner, W. D., & Goldberg, I. J. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000147163.54024.70 · Cited by 125
Karlsson, H., Leanderson, P., Tagesson, C., & Lindahl, M. (2005) · PROTEOMICS · doi:10.1002/pmic.200300938 · Cited by 126
Apolipoprotein B-containing lipoproteins in atherogenesis
Borén, J., Packard, C. J., & Binder, C. J. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01111-0 · Cited by 120
“The mechanisms underlying this observation remain unclear because apoC-III lacks the positively charged domains that are necessary for binding to artery wall proteoglycans 55,56 .”
Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD
Taskinen, M.-R., Packard, C. J., & Borén, J. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0791-9 · Cited by 103
Increased apolipoprotein C3 drives cardiovascular risk in type 1 diabetes
Kanter, J. E., Shao, B., Kramer, F., Barnhart, S., Shimizu-Albergine, M., Vaisar, T., Graham, M. J., Crooke, R. M., Manuel, C. R., Haeusler, R. A., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127308 · Cited by 105
“It is possible that APOC3 enhances the binding of APOB-containing lipoproteins to extracellular matrix (54, 55), or that the increased presence of atherogenic lipoprotein remnants in the artery wall is responsible for accelerated atherosclerosis.”
BackgroundRouland, A., Masson, D., Lagrost, L., Vergès, B. L., Gautier, T., & Bouillet, B. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01703-5 · Cited by 110
Proctor, S. D., Vine, D. F., & Mamo, J. C. L. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000143859.75035.5a · Cited by 103
Regulatory T Cells and Atherosclerosis
Lopez‐Pastrana, J., 沙晓津, Virtue, A., Mai, J., Cueto, R., Lee, I. A., Wang, H., & Yang, X.-F. (2013) · Journal of Clinical & Experimental Cardiology · doi:10.4172/2155-9880.s12-002 · Cited by 114
“The interaction of positively charged APOB with negatively charged proteoglycans leads to the retention of APOB-linked lipoproteins in the arterial vessel wall [21].”
BackgroundTaskinen, M.-R., & Borén, J. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0614-1 · Cited by 90
Chunyu, Z., Christina, K., Katsunori, I., & Sacks, F. M. (2007) · Journal of Lipid Research · doi:10.1194/jlr.p600011-jlr200 · Cited by 95
“In another study, in vitro, apoC-III content of apoB lipoproteins in humans was associated with increased binding affinity to vascular proteoglycan biglycan ( 36 ).”
BackgroundDavidsson, P., Hulthe, J., Fagerberg, B., Olsson, B.-M., Hallberg, C., Dahllöf, B., & Camejo, G. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m500161-jlr200 · Cited by 88
“Furthermore, the findings by Olin-Lewis et al. ( 18 ) clearly documented that there is a significant inverse correlation between LDL size and affinity for the PG biglycan and that the ratio of apoC-III to apoB is an important contributor to this correlation.”
BackgroundRemnant lipoproteins: are they equal to or more atherogenic than LDL?
Salinas, C. A. A., & Chapman, M. J. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000682 · Cited by 87
Proteoglycans in Obesity-Associated Metabolic Dysfunction and Meta-Inflammation
Pessentheiner, A. R., Ducasa, G. M., & Gordts, P. L. S. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00769 · Cited by 80
“When overexpressed in smooth muscle cells of mice lacking low-density lipoprotein receptor (LDLR), it promotes atherosclerosis likely because it enhances the retention of apoCIII-enriched LDL and TRLs in the subendothelial matrix (168, 169).”
BackgroundSascău, R. A., Clément, A., Radu, R., Prisacariu, C., & Stătescu, C. (2021) · Nutrients · doi:10.3390/nu13061774 · Cited by 84
Monocytes and macrophages as protagonists in vascular complications of diabetes
Kanter, J. E., Hsu, C.-C., & Bornfeldt, K. E. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00010 · Cited by 76
“The extracellular matrix, which is responsible for retention of these lipoprotein particles in the artery wall, is expanded and altered under diabetic conditions (39, 42), and VLDL and LDL particles enriched in APOC3 bind better to matrix proteins (97), potentially indicating that under diabetic conditions, macrophage…”
BackgroundMechanism of lipoprotein retention by the extracellular matrix
Gustafsson, M., & Borén, J. (2004) · Current Opinion in Lipidology · doi:10.1097/00041433-200410000-00003 · Cited by 75
Modification of lipoprotein metabolism and function driving atherogenesis in diabetes
Luciani, L., Pedrelli, M., & Parini, P. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117545 · Cited by 72
Lipid-lowering in diabetes: An update
Chait, A., Eckel, R. H., Vrablík, M., & Zambon, A. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117313 · Cited by 81
Self-citationThe effects of apolipoprotein B depletion on HDL subspecies composition and function
Davidson, W. S., Heink, A., Sexmith, H., Melchior, J., Gordon, S. M., Kuklenyik, Z., Woollett, L. A., Barr, J. R., Jones, J. I., Toth, C. A., et al. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m066613 · Cited by 79
Scheffer, P. G., Teerlink, T., Dekker, J. M., Bos, G., Nijpels, G., Diamant, M., Kostense, P. J., Stehouwer, C. D. A., & Heine, R. J. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.103234 · Cited by 66
“Furthermore, apoC-III enhances the binding of apoB-containing lipoproteins to vascular proteoglycans ( 9 ).”
BackgroundExploring apolipoprotein C-III: pathophysiological and pharmacological relevance
Packard, C. J., Pirillo, A., Tsimikas, S., Ference, B. A., & Catapano, A. L. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvad177 · Cited by 61
Immune Response to Lipoproteins in Atherosclerosis
Samson, S., Mundkur, L., & Kakkar, V. V. (2012) · Cholesterol · doi:10.1155/2012/571846 · Cited by 66
“The interaction of positively charged ApoB to negatively charged proteoglycans leads to the retention of ApoB-linked lipoproteins in the vessel wall [10].”
BackgroundOlivieri, O., Martinelli, N., Girelli, D., Pizzolo, F., Friso, S., Beltrame, F., Lotto, V., Annarumma, L., & Corrocher, R. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03720.x · Cited by 73
LDL as a Cause of Atherosclerosis
TOMKIN, G. H. (2012) · The Open Atherosclerosis & Thrombosis Journal · doi:10.2174/1876506801205010013 · Cited by 83
Proteoglycan mediated lipoprotein retention: A mechanism of diabetic atherosclerosis
Tannock, L. R., & King, V. L. (2008) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-008-9078-0 · Cited by 63
Combined dyslipidemia in childhood
Kavey, R.-E. W. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.06.008 · Cited by 66
Ruiz-Narváez, E., Yang, Y., Nakanishi, Y., Kirchdorfer, J., & Campos, H. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m500040-jlr200 · Cited by 61
“Recently, it has been shown that apoC-III increases the ability of apoB-containing lipoproteins to bind to vascular proteoglycans, which may affect the risk of development of atherosclerosis ( 60 ).”
BackgroundOxidation and modification of extracellular matrix and its role in disease
Chuang, C. Y., Degendorfer, G., & Davies, M. J. (2014) · Free Radical Research · doi:10.3109/10715762.2014.920087 · Cited by 57
Koska, J., Yassine, H., Trenchevska, O., Sinari, S., Schwenke, D. C., Yen, F. T., Billheimer, D., Nelson, R. W., Nedelkov, D., & Reaven, P. D. (2016) · Journal of Lipid Research · doi:10.1194/jlr.p064816 · Cited by 55
“It enhances binding of LDL particles to proteoglycans and thereby their retention in the vascular wall, and stimulates production of inflammatory cytokines and adhesion molecules in monocytes and endothelial cells (11-13).”
Apolipoprotein C3: form begets function
Bornfeldt, K. E. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2023.100475 · Cited by 45
“For example, APOC3-containing LDL and VLDL bind better to the vascular proteoglycan biglycan than lipoproteins depleted of APOC3, and this effect is mediated by APOB rather than by direct APOC3 binding to the proteoglycan (69, 70).”
BackgroundSubbotin, V. M. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.05.017 · Cited by 59
ApoCIII: A multifaceted protein in cardiometabolic disease
D'Erasmo, L., Di Costanzo, A., Gallo, A., Bruckert, E., & Arca, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154395 · Cited by 50
Hilpert, K. F., West, S. G., Kris‐Etherton, P. M., Hecker, K. D., Simpson, N., & Alaupovic, P. (2007) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/85.2.369 · Cited by 45
“Additional evidence for the atherogenic potential of LpB:C subclass has been provided by results of another study showing that the apo C-III content of apo B–containing lipoproteins is crucial for their binding to vascular proteoglycan biglycan, a process considered to be a critical step in pathogenesis of atheroscler…”
Bancells, C., Benítez, S., Jauhiainen, M., Ordóñez‐Llanos, J., Kovanen, P. T., Villegas, S., Sánchez‐Quesada, J. L., & Öörni, K. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m800318-jlr200 · Cited by 51
Mendoza, S., Trenchevska, O., King, S. M., Nelson, R. W., Nedelkov, D., Krauss, R. M., & Yassine, H. N. (2017) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2016.12.009 · Cited by 41
Self-citationShin, M., & Krauss, R. M. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.02.025 · Cited by 42
Self-citationThe -omics era: Proteomics and lipidomics in vascular research
Didangelos, A., Stegemann, C., & Mayr, M. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.09.043 · Cited by 42
Ruuth, M. K., Lahelma, M., Luukkonen, P. K., Lorey, M. B., Qadri, S. U., Sädevirta, S., Hyötyläinen, T., Kovanen, P. T., Hodson, L., Yki‐Järvinen, H., et al. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.315766 · Cited by 42
Mangat, R., Su, J. W., Lambert, J. E., Clandinin, M. T., Wang, Y., Uwiera, R. R. E., Forbes, J. M., Vine, D. F., Cooper, M. E., Mamo, J. C. L., et al. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03138.x · Cited by 41
Chapman, M. J., Packard, C. J., Björnson, E., Ginsberg, H. N., & Borén, J. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120529 · Cited by 39
Effects of dietary saturated fat on LDL subclasses and apolipoprotein CIII in men
Faghihnia, N., Mangravite, L. M., Chiu, S., Bergeron, N., & Krauss, R. M. (2012) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2012.118 · Cited by 35
“ApoCIII enriched apoB-containing lipoproteins may be particularly atherogenic by virtue of their decreased affinity for the LDL receptor (12) and increased binding to extracellular vascular proteoglycans (39).”
BackgroundSelf-citationEnhanced extracellular lipid accumulation in acidic environments
Öörni, K., & Kovanen, P. T. (2006) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000245259.63505.c2 · Cited by 40
Hurt‐Camejo, E., & Camejo, G. (2018) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd5030036 · Cited by 41
Triglyceride-Rich Lipoproteins as a Source of Proinflammatory Lipids in the Arterial Wall
Öörni, K., Lehti, S., Sjövall, P., & Kovanen, P. T. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180530094819 · Cited by 38
Umaerus, M., Rosengren, B. E., Fagerberg, B., Hurt‐Camejo, E., & Camejo, G. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.08.040 · Cited by 37
Ruuth, M. K., Äikäs, L., Tigistu‐Sahle, F., Käkelä, R., Lindholm, H. J., Simonen, P. P., Kovanen, P. T., Gylling, H., & Öörni, K. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.314329 · Cited by 34
Recent Advances in Targeted Management of Inflammation In Atherosclerosis: A Narrative Review
Zubirán, R., Neufeld, E. B., Dasseux, A., Remaley, A. T., & Sorokin, A. V. (2024) · Cardiology and Therapy · doi:10.1007/s40119-024-00376-3 · Cited by 33
Kraaijenhof, J. M., Kerkvliet, M., Nurmohamed, N. S., Grefhorst, A., Kroon, J., Wareham, N. J., Hovingh, G. K., Stroes, E. S. G., Boekholdt, S. M., & Reeskamp, L. F. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf037 · Cited by 33
Emerging Targets for Cardiovascular Disease Prevention in Diabetes
Stitziel, N. O., Kanter, J. E., & Bornfeldt, K. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.03.011 · Cited by 30
Retention of atherogenic lipoproteins in atherogenesis
Gustafsson, M. V., Flood, C., Jirholt, P., & Bor�n, J. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-3262-x · Cited by 27
The role of triglycerides in the origin and progression of atherosclerosis
Padró, T., Muñoz‐García, N., & Badimón, L. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2021.02.007 · Cited by 30
Cano, M., Callaway, N. F., Kondo, N., Dike, S., & Handa, J. T. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.04.010 · Cited by 27
“Biglycan has emerged as the most important core protein involved in the initial lipoprotein retention because it localizes to areas of lipoprotein retention before lesion development.(44,45) Versican, however, appears to play a minor role in early lipoprotein retention because it often does not colocalize with lipopro…”
BackgroundLiu, S., Zhang, D., Ju, J., Wang, A., Du, T., Chen, X., Song, Y., Gao, Z., & Xu, H. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1260764 · Cited by 24
“In addition, their larger size compared to LDL, along with their enrichment in apolipoprotein C-III and apolipoprotein E, which increases their affinity for proteoglycans (30, 31), makes them more difficult to return to the arterial lumen.”
BackgroundLähdesmäki, K., Öörni, K., Alanne-Kinnunen, M., Jauhiainen, M., Hurt‐Camejo, E., & Kovanen, P. T. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.10.014 · Cited by 26
“[69] found that the binding of proteoglycans to VLDL derived from different healthy donors correlates positively with the apoC-III content of this lipoprotein class.”
BackgroundInfluentialProtein profiling of low‐density lipoprotein from obese subjects
Karlsson, H., Mörtstedt, H., Lindqvist, H. M., Tagesson, C., & Lindahl, M. G. (2009) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.200800138 · Cited by 21
“hepatic lipase [9], apo E [10], apo C-III [11] and serum amyloid A (SAA) [12] have been described to promote retained interaction in the arterial wall.”
BackgroundApolipoprotein CIII and diabetes. Is there a link?
Christopoulou, E. C., Tsimihodimos, V., Filippatos, T. D., & Elisaf, M. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3118 · Cited by 22
“Lowering ApoCIII may not only improve carbohydrate metabolism but also CVD risk through TRG reduction and other antiatherogenic properties.(97,98) At the moment, limited tools to reduce ApoCIII levels are present.”
BackgroundBeneficial effects of weight loss on plasma apolipoproteins in postmenopausal women
Fernández, M. L., Metghalchi, S., Vega‐López, S., Conde‐Knape, K., Lohman, T. G., & Cordero‐MacIntyre, Z. (2004) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2004.07.001 · Cited by 25
Nahon, J. E., Hoekstra, M., Havik, S. R., van Santbrink, P. J., Dallinga‐Thie, G. M., Kuivenhoven, J. A., Geerling, J. J., & Eck, M. V. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.05.008 · Cited by 23
Blackett, P. R., Blevins, K. S., Quintana, E., Stoddart, M. L., Wang, W., Alaupovic, P., & Lee, E. T. (2005) · Metabolism · doi:10.1016/j.metabol.2004.08.010 · Cited by 20
“It interferes with uptake of chylomicron remnants [25] and binding to the low-density lipoprotein (LDL) receptor [26-28] and facilitates binding of apoB to proteoglycans in the arterial wall after transendothelial passage [29].”
BackgroundLipidomics of triglyceride‐rich lipoproteins derived from hyperlipidemic patients on inflammation
Moreno‐Vedia, J., Llop, D., Rodríguez‐Calvo, R., Plana, N., Amigó, N., Rosales, R., Esteban, Y., Masana, L., Ibarretxe, D., & Girona, J. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14132 · Cited by 19
“The complete lipidome analysis of our study showed that the fatty acid composition associated with the increased release of cytokines includes those particles with lower omega-9 and higher SFA percentages; reduced oleic acid content would also be associated with an increased release of cytokines.”
BackgroundPan, B.-Y., Chen, C.-S., Chen, F.-Y., & Shen, M.-Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312759 · Cited by 19
Kumarapperuma, H., Chia, Z.-J., Malapitan, S. M., Wight, T. N., Little, P. J., & Kamato, D. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.118552 · Cited by 21
Self-citationTang, T., Wilson, P. G., Thompson, J. C., Nelson, C., Yoder, M. H., & Tannock, L. R. (2013) · Journal of Lipid Research · doi:10.1194/jlr.p040139 · Cited by 21
A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy?
Ward, N. C., Chan, D. C., & Watts, G. F. (2022) · BioDrugs · doi:10.1007/s40259-022-00520-2 · Cited by 21
“ApoC-III increases the affinity of LDL for artery wall proteoglycans, increasing subendothelial accumulation of lipoprotein, and increases the enrichment of LDL particles with apoC-III [59, 60].”
BackgroundAdiponectin inhibits the binding of low-density lipoprotein to biglycan, a vascular proteoglycan
Kobayashi, K., Inoguchi, T., Sonoda, N., Sekiguchi, N., & Nawata, H. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.07.048 · Cited by 19
Jayaraman, S., Chavez, O. R., Pérez, A., Miñambres, I., Sánchez‐Quesada, J. L., & Gursky, O. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2020.158712 · Cited by 16
Remnant Cholesterol as an Independent Cardiovascular Risk Factor in Young Adults
Jung, H. N., Heo, J. H., Kim, M., Han, K., Kang, J. G., & Lee, S. J. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.09.015 · Cited by 15
Large-Scale Analysis of Apolipoprotein CIII Glycosylation by Ultrahigh Resolution Mass Spectrometry
Demus, D., Naber, A., Dotz, V., Jansen, B. C., Bladergroen, M. R., Nouta, J., Sijbrands, E. J. G., van Hoek, M., Nicolardi, S., & Wuhrer, M. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.678883 · Cited by 14
Naber, A., Demus, D., Slieker, R. C., Nicolardi, S., Beulens, J. W. J., Elders, P. J. M., Lieverse, A. G., Sijbrands, E. J. G., Hart, L. M. ‘., Wuhrer, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105365 · Cited by 12
“Furthermore, apo-CIII enhances monocyte adhesion to the endothelium [8] and the binding of apoB-containing lipoproteins to vascular proteoglycans [9].”
BackgroundCharacterization of the Metabolic Syndrome by Apolipoproteins in the Oklahoma Cherokee
Alaupovic, P., Blackett, P. R., Wang, W., & Lee, E. T. (2008) · Journal of the CardioMetabolic Syndrome · doi:10.1111/j.1559-4572.2008.00022.x · Cited by 11
Apolipoproteins A-I, B, and C-III and Obesity in Young Adult Cherokee
Wang, W., Blackett, P. R., Khan, S. H., & Lee, E. T. (2017) · Journal of Lipids · doi:10.1155/2017/8236325 · Cited by 12
“Its atherogenic properties are further supported by adverse effects on the arterial wall including enhanced LDL binding to biglycan [29] and proinflammatory effects via nuclear factor kB-mediated VCAM-1 expression and monocyte adhesion [30].”
BackgroundIn the Beginning, Lipoproteins Cross the Endothelial Barrier
Goldberg, I. J., Cabodevilla, A. G., & Younis, W. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22017 · Cited by 10
“Thus, apoB structure is likely affected by the length of the protein, the size of its carrier lipoprotein, and other associated proteins (apolipoproteins, such as apoC3 52) ).”
BackgroundReijnders, E., van der Laarse, A., Ruhaak, L. R., & Cobbaert, C. M. (2024) · Clinical Proteomics · doi:10.1186/s12014-024-09465-w · Cited by 12
“ApoC-III has also been reported to facilitate LDL retention in the arterial wall [20, 102].”
BackgroundCombined Dyslipidemia in Children and Adolescents
Kavey, R.-E. W. (2016) · Cited by 9
Subramanian, S., & Chait, A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65798-7 · Cited by 9
Self-citationBjörnson, E., Adiels, M., Taskinen, M., Packard, C. J., & Borén, J. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01399-y · Cited by 9
“Lipoprotein Retention in the Artery Wall ApoC-III increases the affinity of atherogenic lipoproteins for pro - teoglycans, facilitating their retention in the subendothelial space [62, 63].”
Hypertriglyceridemia, a causal risk factor for atherosclerosis, and its laboratory assessment
Wieczorek, E., Ćwiklińska, A., & Jankowski, M. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-0189 · Cited by 8
Ohwada, T., Sakamoto, T., Suzuki, S., Sugawara, Y., Sakamoto, K., Ikeda, A., Haga, F., Sato, T., Nakazato, K., Takeishi, Y., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-18914-1 · Cited by 8
O-glycoprofiling of Serum Apolipoprotein C-III in Colorectal Cancer
Kianičková, K., Pakanová, Z., Květoň, F., Holazová, A., Kundalia, P. H., Baráth, P., Miljuš, G., Nedić, O., & Katrlík, J. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2901032 · Cited by 6
“ApoC-III has been known to promote atherogenicity by enhancing the affinity of LDL for proteoglycans of the arterial walls [29], facilitating interaction between monocytes and endothelial cells [30], promoting the proliferation of smooth muscle cells, and alternating thrombocyte activity by…”
BackgroundA novel assay to measure low-density lipoproteins binding to proteoglycans
Geh, E. N., Swertfeger, D. K., Sexmith, H., Heink, A., Tarapore, P., Melchior, J., Davidson, W. S., & SHAH, A. S. (2024) · PLoS ONE · doi:10.1371/journal.pone.0291632 · Cited by 3
Llop, D., Rehues, P., Paredes, S., Guardiola, M., Girona, J., Rosales, R., Esteban, Y., Masana, L., Ibarretxe, D., Vallvé, J.-C., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02553-z · Cited by 3
Elevated levels of apolipoprotein C3 impair platelet function and reduce thrombosis
Schrottmaier, W. C., Kral-Pointner, J. B., Mußbacher, M., Salzmann, M., Hochreiter, B., Pirabe, A., Reiter, T., Badrnya, S., Schmid, J. A., Volf, I., et al. (2026) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2026.01.004 · Cited by 3
Contribución de la apolipoproteína CIII a la aterogenicidad de las dislipidemias
Camejo, G., & Davidsson, P. (2012) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2012.02.006 · Cited by 3
“Experimentos de Chait et al. muestran que la afinidad de la LDL y de la VLDL por los proteoglicanos arteriales se incrementa con el contenido de apoCIII en las lipoproteínas 34,36,37 .”
Han, T., Woo, S.-K., Shin, S., & Kang, H. (2006) · Annals of Nutrition and Metabolism · doi:10.1159/000089562 · Cited by 2
“High circulating apoC-III levels have been associated with increased risk for atherosclerosis and coronary artery diseases (CAD) [ , ,”
Xiang, P., Hanjani, K., & Francis, G. A. (2026) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000001028 · Cited by 2
Mundkur, L., & Kakkar, V. V. (2015) · Global Journal of Immunology and Allergic Diseases · doi:10.14205/2310-6980.2014.02.02.2 · Cited by 1
Metadata
- Authors
- Olin-Lewis, K., Krauss, R. M., La Belle, M., Blanche, P. J., Barrett, P. H. R., Wight, T. N., & Chait, A.
- Affiliations
- Lawrence Berkeley National Laboratory (US)
- The University of Western Australia (AU)
- University of Washington (US)
- Corresponding author
- Chait, Alan
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2002-11
- Volume
- 43
- Issue
- 11
- Pages
- 1969-1977
- ISSN
- 0022-2275 (ISSN-L)
- OpenAlex
- W2015816213
- Cited by
- 114
- References
- 54
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 10 · 2023: 6 · 2022: 4 · 2021: 7 · 2020: 10 · 2019: 2 · 2018: 5 · 2017: 1 · 2016: 7 · 2015: 3 · 2014: 3 · 2013: 2 · 2012: 6
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6514 d)
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (HL30086)
- U.S. Public Health Service (12609)
- National Heart, Lung, and Blood Institute (P01HL030086, HL3-0086, HL 18754)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 02456, DK35816-16, P30DK035816)
- National Center for Research Resources
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Proteoglycans and glycosaminoglycans research
- Keywords
- apolipoprotein C-III, biglycan, apolipoprotein B, apolipoprotein E, VLDL, IDL, low-density lipoprotein, atherosclerosis, atherogenesis, arterial smooth muscle cells, immunoaffinity chromatography
- MeSH terms
- Apolipoproteins B, Apolipoproteins C, Chromatography, Affinity, Humans, Lipoproteins, Lipoproteins, LDL, Lipoproteins, VLDL, Particle Size, Proteoglycans, Extracellular Matrix Proteins, Apolipoprotein C-III, Biglycan
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.